Source: International Congress 2015 – Immune aspects of asthma and other airway diseases
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Robert K. Zeldin (Garches, France), Robert K. Zeldin, Martine Le Gall, Patricia Rodriguez, Yann Amistani, Pascal Demoly. High doses of sublingual tablets of house dust mite allergen extracts: Lung function assessment in a phase I study in adults with mite-associated allergic asthma. Eur Respir J 2015; 46: Suppl. 59, 4018

Member's Comments

No comment yet.

Related content which might interest you: Sublingual tablets of house dust mite allergen extracts: Results of a phase I study in adults with mite-associated allergic asthma Source: Annual Congress 2013 –Studies of asthma in man Year: 2013 Safety of subcutaneous immunotherapy with standardized extracts of house dust mite in allergic asthmatic subjects Source: Eur Respir J 2002; 20: Suppl. 38, 57s Year: 2002 Collaborative treatment with variety of dust mites allergic in standardized dermatophagoides pteronyssinus allergen immunotherapy Source: International Congress 2016 – Clinical studies in asthma and immunology Year: 2016 Safety of 5-grass pollen extract sublingual tablet in patients with grass pollen-induced allergic rhinoconjunctivitis and concomitant intermittent asthma: A pooled analysis Source: Annual Congress 2013 –Treatment of asthma Year: 2013 Association between Th2 biomarker levels and efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Clinical efficiency of sublingual and subcutaneous allergenspecific immunotherapy with household dust mite allergen in patients with persistent allergic rhinitis Source: Eur Respir J 2006; 28: Suppl. 50, 438s Year: 2006 House dust mite sublingual immunotherapy reduces type 2 biomarkers in allergic asthma Source: Virtual Congress 2020 – Management of allergy, asthma and COPD Year: 2020 Effects of 3-yr immunotherapy with standardised extracts of house dust mite in allergic asthmatic subjects receiving appropriate drug treatment Source: Eur Respir J 2002; 20: Suppl. 38, 107s Year: 2002 Efficacy of specific allergy vaccination in house dust mite asthma Source: Eur Respir J 2005; 26: Suppl. 49, 465s Year: 2005 Prevention of paediatric asthma and allergy by reduction of house dust mite content Source: Eur Respir J 2001; 18: Suppl. 33, 287s Year: 2001 Sublingual immunotherapy is an established therapy for house dust mite sensitive allergic rhinitis and/or asthma Source: Annual Congress 2007 - Improving asthma therapy - new findings in established and experimental treatment modalities Year: 2007 OPURIT: Omalizumab-protected ultra rush specific immunotherapy in severe asthmatic patients with house dust mite allergy Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Sensitisation to house dust mite: its association with bronchial hyperresponsiveness and lung function in asthmatic children Source: Annual Congress 2009 - FeNO and other biomarkers in childhood asthma Year: 2009 Diagnostic utility of serum periostin for house dust mite sublingual immunotherapy response in allergic rhinitis Source: Virtual Congress 2021 – Asthma and COPD meets COVID-19: new diagnostic tools and results from clinical trials Year: 2021 Hypoallergenic high dose scit as add-on therapy in children with allergic asthma caused by house dust mites Source: Annual Congress 2009 - Clinical aspects of inflammatory airways diseases Year: 2009 Effect of house dust mite sublingual immunotherapy on airway inflammation and remodeling in allergic asthma with rhinitis Source: International Congress 2019 – Precision meets immunology in treatment of airway diseases Year: 2019 Young Investigator session: Inhibition of airway hyperresponsiveness and inflammation by vaccination against IL-33 in a house dust mite model of asthma Source: Lung Science Conference 2014 - Lung Inflammation and Immunity Year: 2014 LSC 2014 abstract - Influenza-induced exacerbation in a murine chronic house dust mite (HDM) asthma model Source: International Congress 2014 – Exploring molecular mechanisms of allergy and asthma in animal models Year: 2014 Omalizumab is equally effective in persistent allergic oral corticosteroid-dependent asthma whether due to seasonal allergens or to perennial allergens Source: International Congress 2015 – Asthma and lung immunology Year: 2015 HDM sublingual AIT tablet is well-tolerated and effective in partly and uncontrolled allergic asthma Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases Year: 2014